13 results
To evaluate LFS after allo HCT in AML/RAEB in complete remission using matched or unrelated donors in comparison to conventional chemotherapy
Key objective The key objective of the study to determine whether it is necessary to boost the healthy population in autumn. Primary endpoint: The primary endpoint is to determine the fold change in antibody level at day of boost and 28 days after…
The primary objective is to compare the efficacy of Tec-Dara (Arm A) with DPd/DVd (Arm B) in participants who have received 1 to 3 prior lines of therapy, including a PI and lenalidomide.
Primary objectiveTo assess in which percentage of patients the AUC/MIC ratio is above the target of 270 µg*h/L and Ctrough is above the target EC50 (2.7 µg/L) during usage of pomalidomide 4 mg every day, pomalidomide 4mg every other day, and…
Primary objective: To compare the efficacy of JNJ-68284528 with standard therapy, either pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).
Primary Objective** To compare the PFS of melflufen plus dexamethasone (Arm A) versus pomalidomide plus dexamethasone (Arm B) as assessed by the Independent Review Committee (IRC) according to the International Myeloma Working Group Uniform Response…
Primary objectiveThe key objective is to examine the anti-body immune response to SARS-CoV-2 vaccination in shift workers, compared to dayworkers, Secondary objectives:• To tinvestigate whether sleep duration, independent of circadian misalignment,…
The purpose of this study is to evaluate the effects of the addition of daratumumab to pomalidomide and dexamethasone in subjects with relapsed or refractory MM.1. Primary objectiveThe primary objective of this study is to compare PFS between…
Primary objectivesMeasuring the SARS-CoV-2-specific immune response against SARS-CoV-2 after inoculation with a single-dose Janssen compared to a homologous vaccination regimen with Janssen /Janssen and the comparison of a homologous vaccination…
The study will look at patients with relapsed (returned after prior treatment) and refractory (not responsive to prior treatment) multiple myeloma. The research aims to compare a new drug called elotuzamab combined with standard of care (…
Primary ObjectiveThe primary objective of the study is to determine the recommended dose and regimen ofdurvalumab either as monotherapy or in combination with POM +/- dex in subjects with RRMM.Secondary ObjectivesThe secondary objectives are to:*…
Primary objectives- Evaluate the efficacy, defined as PFS, of pomalidomide maintenance plus dexamethasone versus pomalidomide maintenance in patients who responded (>= PR) to the combination of pomalidomide (POM), carfilzomib (CAR) and low…
The primary objective of the study is to compare the PFS of SPd versus EloPd in patients with MM who have received 1 to 4 prior anti-MM lines of therapy and never received pomalidomide, selinexor, or elotuzumab. Patients must have had prior…